Diagnostic and Prognostic Value of microRNA-21 in Colorectal Cancer: An Original Study and Individual Participant Data Meta-analysis

Zhang, Honghe; Li, Peiwei; Ju, Haixing; Pešta, Martin; Kulda, Vlastimil; Jin, Wenjun; Cai, Mao; Liu, Changbao; Wu, Han; Xu, Jun; Yao, Ye; Zhang, Guanglin; Xu, Enbo; Cai, Jianting; Lai, Maode; Xia, Dajing; Yang, Jun; Wu, Yihua

doi:10.1158/1055-9965.epi-14-0598

Cited by 27 publications

(26 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be due to the breakdown of the miRNA in the plasma samples. However, the majority of the previous studies in NSCLC did not examine the exosomal miRNAs separated from the plasma or serum, which would likely include the intact miRNA (7)(8)(9)(10)(11)(12)(13)(26)(27)(28)(29). In the present study, microarray-based expression profiling of miRNAs derived from exosomes in the plasma of 6 NSCLC patients with or without recurrence was employed.…”

Section: Discussionmentioning

confidence: 99%

“…From these results, miR-4257 and miR-21 were selected as recurrence-specific biomarkers for NSCLC patients. It has been reported that serum miR-21 is significantly associated with the promotion of tumor growth, proliferation and progression, and the response of cancer to chemotherapy (26). In an evaluation of clinicopathological significance, Wang et al reported that serum miR-21 expression was significantly correlated with advanced TNM stage and the presence of lymph node metastasis in NSCLC patients (27).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. Predictive biomarkers for the recurrence of non-small cell lung cancer (NSCLC) in patients who have received curative resection are important for cancer treatment. The functional microRNAs (miRNAs/miRs) in the exosomes of plasma and serum samples are of interest as stable and non-invasive biomarkers for recurrence in cancer patients. The aim of the present study was to clarify the usefulness of plasma exosomal miRNAs as biomarkers for the prediction of recurrence in NSCLC following curative resection. First, microarray-based expression profiling of miRNAs derived from exosomes in the plasma of 6 patients was employed to identify a biomarker that distinguishes between patients with and without NSCLC recurrence. In the miRNA microarray analyses, the exosomal miR-21 and miR-4257 levels of the NSCLC patients showed marked upregulation in those individuals with recurrence compared with those without recurrence and healthy individuals. These two miRNAs were thus selected as recurrence-specific biomarkers and their potential was evaluated in a separate cohort of 195 NSCLC patients. In comparison to the levels in 30 healthy individuals, exosomal miR-21 and miR-4257 levels showed a significant increase in the NSCLC patients (P<0.01). When evaluating the clinicopathological significance of these miRNAs, exosomal miR-21 showed a significant association with tumor size and tumor-node-metastasis (TNM) stage (P<0.05). Exosomal miR-4257 showed a significant association with histological type, lymphatic invasion and TNM stage (P<0.05). The disease-free survival (DFS) rates of high exosomal miR-21 patients were significantly worse than those of low exosomal miR-21 patients (P<0.05), and the DFS rates of patients with high exosomal miR-4257 levels were significantly worse than those with low exosomal miR-4257 levels (P<0.01). In the Cox multivariate analysis, plasma exosomal miR-21 and miR-4257 expression showed a significance association with DFS (P<0.05). These results suggest that plasma exosomal miR-21 and mir-4257 expression has potential as a predictive biomarker for recurrence in NSCLC patients who have received curative resection. IntroductionLung cancer, mainly non-small cell lung cancer (NSCLC), is the leading cause of cancer-associated mortality globally. More than 133,000 new diagnoses and over 77,000 associated mortalities are expected to occur in 2015 in Japan (1). In spite of progress in NSCLC therapy, the prognosis for patients with NSCLC remains poor (2). Therefore, clarification of the biomarkers most likely to predict the recurrence of NSCLC after curative surgery is required to improve the outcome of NSCLC patients.MicroRNAs (miRNAs/miRs) are one of the most compelling molecular markers in the diagnosis and prognosis of tumors (3,4). miRNAs are short (20-24 nt) non-coding RNAs that take part in the post-transcriptional regulation of gene expression in multicellular organisms by impacting mRNA stability and translation. miRNAs target protein-coding mRNAs at the post-transcriptional level by directly c...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Many previous studies screened for microRNA with significantly different expressions using a microRNA microarray in a small sample size and then validated the results by qRT‐PCR in a larger sample size. Thus, numerous systematic reviews and meta‐analyses have described the diagnostic efficiencies of microRNA . Most of these studies reviewed only 1 microRNA, while others reviewed all microRNA and conducted meta‐analyses including all of the diagnostic tests.…”

Section: Discussionmentioning

confidence: 99%

Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods

Liu

et al. 2018

Cancer Science

View full text Add to dashboard Cite

Recently, many new diagnostic biomarkers have been developed for colorectal cancer. We chose 2 methods with high diagnostic efficiency, the detection of serum microRNA and metabolomics based on gas chromatography/mass spectrometry (GC/MS), and aimed to establish appropriate models. We reviewed the diagnostic value of all microRNA identified by previous diagnostic tests. We selected appropriate microRNA to validate their diagnostic efficiency, and determined the optimal combination. We included 85 patients with colorectal cancer (CRC) and 78 healthy controls (HC) and detected the expression of the microRNA. GC/MS analysis was conducted, and we used 3 multivariate statistical methods to establish diagnostic models. The concentrations of carcinoembryonic antigen (CEA) and carbohydrate antigen 19‐9 (CA19‐9) were detected for comparison with the novel models. Ultimately, 62 published studies and 63 microRNA were included in this review. MiR‐21, miR‐29a, miR‐92a, miR‐125b and miR‐223 were selected to further validate their diagnostic value. The serum levels of the 5 microRNA in CRC patients were significantly higher than those in the HC. The combination of miR‐21, miR‐29a, miR‐92a and miR‐125b had the highest area under the curve (AUC) at 0.952, with a sensitivity of 84.7% and a specificity of 98.7%. The GC/MS analysis exhibited an excellent diagnostic value and the AUC reached 1.0. With regard to traditional biomarkers, the AUC of CEA and CA19‐9 were 0.808 and 0.705, respectively. The application prospects are good for microRNA and metabolomics as new diagnostic methods because of their high diagnostic value compared with traditional biomarkers.

show abstract

“…One of most extensively investigated miRNA is miR-21 whom tissue expression was reported to be independently associated with poor prognosis by two meta-analyses (65,66). The first study demonstrating that high levels of serum (rather than tissue) miR-21 indicate a poor prognosis in patients with CRC, was published in 2013 by Toiyama and coauthors (67).…”

Section: Prognostic Role Of Circulating Mirnasmentioning

confidence: 99%

Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers

Danese

Montagnana

2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers worldwide and the second leading cause of cancer-related mortality in western countries. Despite the high incidence, treatment options for advanced CRC remain limited and unsuccessful, resulting in a poor prognosis. Therefore, novel accurate diagnostic, prognostic and predictive biomarkers are clearly and urgently needed to detect advanced colon polyps and early stage CRC and to identify the most effective treatments for specific CRC patients. CRC is known to develop from early premalignant lesions to full blown cancer via a multi-step process involving a series of genetic mutations that accumulate over time. Recent improvement of our understanding of CRC biology and advances in genomic technologies has led to the identification of a variety of epigenetic alterations strongly involved in cancer initiation and progression. Among the epigenetic marks implicated in CRC the most widely studied are the global DNA hypomethylation, the promoter hypermethylation and the miRNAs dysregulations. Many evidence exist that such tumour associated alterations may serve as new potential biomarkers. Moreover, due the non-invasive, objective, and potential reproducible assessment, circulating epigenetic biomarkers have reached increasing attentions in the last few years. In this review, we attempt to analyze the existing most recent literature on the role of circulating DNA methylations and miRNAs alterations in CRC diagnosis and prognosis.

show abstract

Diagnostic and Prognostic Value of microRNA-21 in Colorectal Cancer: An Original Study and Individual Participant Data Meta-analysis

Cited by 27 publications

References 48 publications

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

Exosomal microRNA in plasma as a non-invasive biomarker for the recurrence of non-small cell lung cancer

Serum microRNA signatures and metabolomics have high diagnostic value in colorectal cancer using two novel methods

Epigenetics of colorectal cancer: emerging circulating diagnostic and prognostic biomarkers

Contact Info

Product

Resources

About